July 10, 2017
CTI Clinical Trial and Consulting Services Announces Addition of Health Economics and Outcomes Research Directors
FOR IMMEDIATE RELEASE [Covington, KY ~ July 10, 2017]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization proudly announces the additions of Frank Ernst, PharmD, MS and Michael Minshall, MPH to their Health Economics and Outcomes Research (HECOR) department.
"Both Frank and Michael will be huge assets to the CTI HECOR team, leading complex real world evidence programs for our clients, as well developing our internal team members," said Lynn Fallon, President. "As our business continues to expand, both will play a large role in the leadership and development of this department."
Frank R. Ernst, PharmD, MS joins as Executive Director, Health Economics and Outcomes Research
Dr. Ernst will lead the HECOR team to ensure high quality deliverables and customer service, develop and conduct research studies for our clients, and play a strategic role as we expand our HECOR group. Dr. Ernst has more than 18 years of experience developing, conducting, managing, and disseminating pharmacoeconomic, outcomes, utilization, and market research studies involving large and small retrospective database studies of medications and medical devices across a wide variety of clinical therapeutic areas ranging from infectious disease to oncology to rare diseases. His experience and expertise includes medical chart review studies, retrospective hospital and claims databases, and registry data analyses.
Previously, Dr. Ernst served as Senior Director/Chief Science Officer - Health Economics and Outcomes Research for Cardinal Health, Vice President of Health Economics and Outcomes Research for Indegene Lifesciences, and Principal in Applied Research for Premier, Inc. His research has been presented at scientific conferences in the US and internationally, and he has been published in peer-reviewed medical and pharmacy journals more than 175 times. He also completed an industry-sponsored Global Outcomes Research Fellowship. Dr. Ernst earned his Doctor of Pharmacy degree and his MS in Pharmacoeconomics, Policy, and Outcomes Research from the University of Arizona.
Michael E. Minshall, MPH joins as Senior Director, Health Economics and Outcomes Research
Minshall comes to CTI with many years of leadership experience in health economics and outcomes research, having spent time in pharmaceuticals, medical devices, management consulting, and a healthcare payer. Minshall will take a large role in business development, project execution and personnel management of the CTI HECOR team. His experience and expertise includes client/payer economic strategy and implementation, among a wide variety of other experiences in pharmacoeconomics and outcomes research studies.
Prior to joining CTI, Minshall lead a team of research scientists at Humana, Inc. in performing health economics and outcomes research studies to support cost-effectiveness in healthcare delivery. He began his career at Eli Lilly & Company where he worked for over a decade in a variety of Global Health Economics and Outcomes Research positions. He also served as Senior Director, HECOR at DJO Global and Covidien, and Principal, HECOR, at IMS-Health. Minshall also owned and operated his own HECOR consulting firm. He earned his Bachelor of Science (Biology) from Alma College and his Masters in Public Health (Epidemiology) from the University of Texas Health Science Center at Houston.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com